FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) in combination with trastu… [Video]

Listen to a soundcast of the May 5, 2021 FDA approval of Keytruda (pembrolizumab) combined with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for first-line treatment of locally advanced unresectable/ metastatic HER2 positive gastric or gastroesophageal junction adenocarcinoma.